Bio News
Researchers at Shanghai Jiao Tong University confirmed a 40% complete response rate in a phase 2 clinical trial involving 90 patients with high-risk rectal cancer. The researchers applied a personalized neoadjuvant treatment strategy that selected targeted therapies according to RAS gene status. The strategy increased the rate of anal sphincter-preserving surgery to approximately 90%.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
